TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03600129
Drug: 30 milliliters of 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
Study: NCT02000947
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
Study: NCT01684605
Drug: NESP 60μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated NESP 60μg once intravenously
Study: NCT01684605
Drug: CKD-11101 60μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated CKD-11101 60μg once intravenously
Study: NCT02274428
Drug: pneumostem
Approvals — FDA: no, EMA: no, PMDA: no
Description: human umbilical cord blood derived mesenchymal stem cells
Study: NCT01793935
Drug: Sensoril®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
Study: NCT01793935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
Study: NCT06161090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT04215770
Drug: inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
Study: NCT01726686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03907423
Drug: Rosuvastatin10 mg tablet
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Study: NCT03907423
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Study: NCT00189514
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
Study: NCT03535870
Drug: Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Study: NCT02927314
Drug: CF102
Normalized name: Cannabinoid Receptor Agonist CF102
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT02927314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT00265291
Drug: fluoxetine or desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine 5-40 mg/day desipramine 50-150 mg/day
Study: NCT03535870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo dry powder administered via the LOMI inhaler device
Study: NCT00306072
Drug: nutritional herbal extract from Salacia oblonga
Normalized name: Cydonia oblonga leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02245373
Drug: Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01540734
Drug: Marketed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed formulation
Study: NCT01540734
Drug: Experimental paracetamol formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formulation
Study: NCT00081458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injectable subcutaneously daily into thigh or abdomen
Study: NCT03523351
Drug: Systemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
Study: NCT04505917
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
Study: NCT03818932
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03818932
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT03818932
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT01197235
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of isotonic saline will be performed 1 hour before angiography
Study: NCT02475057
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
Study: NCT02400580
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in the treatment arm will receive 1000mg of IV acetaminophen.
Study: NCT02400580
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in the placebo arm will receive normal saline.
Study: NCT00726427
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation to achieve maximum tolerated dose
Study: NCT00726427
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose
Study: NCT02080078
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00827242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
Study: NCT02842099
Drug: TA or TAC
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol, Epirubincin, with or without Cyclophosphamide
Study: NCT01479530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily; tablet; orally; 16 weeks
Study: NCT01479530
Drug: Azilect®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily; tablet; orally; 16 weeks
Study: NCT01119222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
Study: NCT00380523
Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04806425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline is given in same volume to normal saline group over the same duration
Study: NCT04452006
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be provided in HPMC capsules for oral administration.
Study: NCT01677065
Drug: Immediate-release reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration of reference drug under fasted conditions
Study: NCT04126668
Drug: CM082 with fed or fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
Study: NCT02931110
Drug: CBL0137
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
Study: NCT03234751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 hours of placebo.
Study: NCT02059460
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03193931
Drug: Methotrexate Injectable Solution
Normalized name: methotrexate Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
Study: NCT02117817
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04162275
Drug: Finamine tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken Finamine tablets orally
Study: NCT04162275
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken Placebo tablets orally
Study: NCT04738162
Drug: 5-Aminolevulinic Acid Hydrochloride, Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
Study: NCT00327132
Drug: Omeprazole, Amoxicillin, Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00604383
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, orally, daily, up to 42 months
Study: NCT02298283
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
Study: NCT03012347
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
Study: NCT03428854
Drug: LNG-IUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levnorgestrel containing IUD
Study: NCT00520442
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00520442
Drug: acetamin w codeine
Normalized name: acetaminophen / codeine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02069366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
Study: NCT00649623
Drug: Benicar® Tablets 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg, single dose fasting
Study: NCT01111292
Drug: Inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04928586
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTD-ILD patients treated with DMARDs according to the condition of the disease
Study: NCT03338023
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03338023
Drug: Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03341429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injection
Study: NCT02523638
Drug: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Study: NCT01068912
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID x 1 day, and Placebo BID x 4 days
Study: NCT03650608
Drug: Cohort 1: HL217 Ophathalmic Solution QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 (Once a day)
Study: NCT03650608
Drug: Cohort 2: HL217 Ophathalmic Solution BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 (Twice a day)
Study: NCT03650608
Drug: Cohort 3: HL217 Ophthalmic Solution QID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3 (Four times a day)
Study: NCT03650608
Drug: Placebo Ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00356421
Drug: Inhaled Human Insulin (Exubera®)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial inhaled insulin regimen and administration of insulin glargine QD
Study: NCT00567112
Drug: 10 mg MK-0941 DFC (fasted)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
Study: NCT00567112
Drug: 10 mg MK-0941 OCT (after meal)
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
Study: NCT00567112
Drug: 10 mg MK-0941 OCT (before meal)
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
Study: NCT00567112
Drug: 10 mg MK-0941 OCT (fasted)
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
Study: NCT00918450
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed
Study: NCT01890005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
Study: NCT03528577
Drug: Zero-dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A
Study: NCT03528577
Drug: 90 mcg of PROAIR® HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B
Study: NCT03528577
Drug: 180 mcg of 90 mcg of PROAIR® HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C
Study: NCT01789775
Drug: Drug: CD07805/47 gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01789775
Drug: CD07805/47 gel Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01940146
Drug: SPARC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01940146
Drug: SPARC1310 II
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARC1310 II
Study: NCT01940146
Drug: SPARC1310 III
Normalized name: CARDIOTOXIN III
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPARC1310 III
Study: NCT04947267
Drug: 2% Mepivacaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
Study: NCT03879109
Drug: Chemotherapy FOLFIRINOX, 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)
Study: NCT04926584
Drug: induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy
Study: NCT03664141
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with cannabis oil
Study: NCT03664141
Drug: Placebo/ Regular Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo (Regular Oil)
Study: NCT04338997
Drug: IZD174
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitor of NLRP3
Study: NCT00705822
Drug: Docetaxel + Estramustine + Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks
Study: NCT01328626
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
Study: NCT01724190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04119336
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously on days 1, 8, 15.
Study: NCT00442689
Drug: ethinyl estradiol 35 mcg and drospirenone 3 mg
Normalized name: drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one active pill per day for three weeks and then 1 sugar pill per day for one week
Study: NCT02205814
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection of placebo
Study: NCT00198120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: same dosing schedule and capsule strength
Study: NCT01283386
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
Study: NCT01437046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04337073
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
Study: NCT01531153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose.
Study: NCT01324180
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2/day IV over 15 minutes on day 2
Study: NCT04515966
Drug: Methylprednisolone Injection [Solu-Medrol]
Normalized name: methylprednisolone Injection [Solu-Medrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
Study: NCT02573467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Study: NCT00335192
Drug: Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
Study: NCT04328285
Drug: Placebo of LPV/r Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
Study: NCT00167882
Drug: 5-aminosalicylate (Pentasa, Ferring)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01560988
Drug: Borage and Echium Seed Oils
Normalized name: Echium plantagineum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
Study: NCT02056288
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
Study: NCT01557816
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
Study: NCT01557816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for seven days given BID during either of the 2 treatment periods.
Study: NCT00425360
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01243125
Drug: NVC-422, 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Study: NCT01243125
Drug: Sterile normal saline, 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Study: NCT04286503
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic treatment
Study: NCT00351104
Drug: Ketoprofen Topical Patch 20%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03319121
Drug: Empirical therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
Study: NCT03319121
Drug: Guided therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
Study: NCT02746380
Drug: Humira®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab